Furthermore, breast cancer is a highly heterogeneous disease, and molecular subtypes such as TNBC, HER2-enriched, Luminal A, and Luminal B are known to exhibit distinct biological behaviors, treatment responses, and prognoses. This evidence concerns the gene ERBB2 and breast carcinoma.